These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 11591906

  • 1. Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration.
    Pea F, Brollo L, Lugano M, Dal Pos L, Furlanut M.
    Ther Drug Monit; 2001 Oct; 23(5):587-8. PubMed ID: 11591906
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA, Hudson JQ, Hill DM, Swanson JM, Wood GC, Laizure SC, Arnold-Ross A, Hu ZY, Hickerson WL.
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of teicoplanin during continuous hemofiltration with a new and a 24-h used highly permeable membrane: rationale for therapeutic drug monitoring-guided dosage.
    Meyer B, Traunmüller F, Hamwi A, Hollenstein UM, Locker GJ, Sperr WR, Staudinger T, Thalhammer-Scherrer R, Burgmann H, Thalhammer F.
    Int J Clin Pharmacol Ther; 2004 Oct; 42(10):556-60. PubMed ID: 15516025
    [Abstract] [Full Text] [Related]

  • 4. [Influence of arteriovenous hemofiltration on teicoplanin pharmacokinetics].
    Choufane S, Lobjoie E, Tinturier F.
    Ann Fr Anesth Reanim; 1996 Oct; 15(8):1168-72. PubMed ID: 9636789
    [Abstract] [Full Text] [Related]

  • 5. Influence of arterio-venous haemofiltration on teicoplanin elimination.
    Hillaire-Buys D, Peyriere H, Lobjoie E, Bres J, Ossart M, Despaux E.
    Br J Clin Pharmacol; 1995 Jul; 40(1):95-7. PubMed ID: 8527277
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
    Tegeder I, Bremer F, Oelkers R, Schobel H, Schüttler J, Brune K, Geisslinger G.
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2640-5. PubMed ID: 9420033
    [Abstract] [Full Text] [Related]

  • 7. Imipenem/cilastin dosage during acute renal failure and hemofiltration.
    Dehne MG, Kroh UF.
    Intensive Care Med; 1995 Oct; 21(10):863. PubMed ID: 8557879
    [No Abstract] [Full Text] [Related]

  • 8. [Glycopeptides (vancomycin, teicoplanin)].
    Furuta I, Kitahashi T.
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():423-6. PubMed ID: 15658354
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
    Alarabi AA, Cars O, Danielson BG, Salmonson T, Wikström B.
    J Antimicrob Chemother; 1990 Jul; 26(1):91-8. PubMed ID: 2211452
    [Abstract] [Full Text] [Related]

  • 10. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration.
    Mueller BA, Scarim SK, Macias WL.
    Am J Kidney Dis; 1993 Feb; 21(2):172-9. PubMed ID: 8430678
    [Abstract] [Full Text] [Related]

  • 11. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity.
    Matthews PC, Chue AL, Wyllie D, Barnett A, Isinkaye T, Jefferies L, Lovering A, Scarborough M.
    J Infect; 2014 Jan; 68(1):43-9. PubMed ID: 24012820
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101.
    Norrby SR, Burman LA, Sassella D, Corigli R, Cassinelli G, Franceschi G, Dornbusch K.
    J Antimicrob Chemother; 1990 Mar; 25(3):371-83. PubMed ID: 2338416
    [Abstract] [Full Text] [Related]

  • 13. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C, Tsuji Y, Muraki Y, Mizoguchi A, Okuda M, To H.
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [Abstract] [Full Text] [Related]

  • 14. Teicoplanin pharmacokinetics in pediatric patients.
    Dufort G, Ventura C, Olivé T, Ortega JJ.
    Pediatr Infect Dis J; 1996 Jun; 15(6):494-8. PubMed ID: 8783345
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of teicoplanin in patients undergoing chronic haemodialysis.
    Papaioannou MG, Marinaki S, Pappas M, Stamatiadis D, Giamarellos-Bourboulis EJ, Giamarellou H, Stathakis C.
    Int J Antimicrob Agents; 2002 Mar; 19(3):233-6. PubMed ID: 11932147
    [Abstract] [Full Text] [Related]

  • 16. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
    Vos MC, Vincent HH, Yzerman EP.
    Intensive Care Med; 1992 Mar; 18(5):282-5. PubMed ID: 1527259
    [Abstract] [Full Text] [Related]

  • 17. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients.
    Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A.
    Intensive Care Med; 1999 Oct; 25(10):1100-4. PubMed ID: 10551965
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of Teicoplanin Trough Values After the Recommended Loading Dose in Children With Associated Safety Analysis.
    Yamada T, Kubota T, Yonezawa M, Nishio H, Kanno S, Yano T, Kobayashi D, Egashira N, Takada H, Hara T, Masuda S.
    Pediatr Infect Dis J; 2017 Apr; 36(4):398-400. PubMed ID: 27977550
    [Abstract] [Full Text] [Related]

  • 19. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T, Li N, Hu S, Xie J, Lei J, Wang Y, Zheng X, Xing J, Dong Y.
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [Abstract] [Full Text] [Related]

  • 20. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH, Kang CI, Huh K, Cho SY, Chung DR, Lee SY, Kim YJ, Peck KR.
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.